Combined Blockade of Lipid Uptake and Synthesis by CD36 Inhibitor and SCD1 siRNA Is Beneficial for the Treatment of Refractory Prostate Cancer DOI Creative Commons
Jiyuan Chen, Xiaoyan Yu, Gang Yang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Drug resistance is an important factor for prostate cancer (PCa) to progress into refractory PCa, and abnormal lipid metabolism usually occurs in which presents great challenges PCa therapy. Here, a cluster of differentiation 36 (CD36) inhibitor sulfosuccinimidyl oleate sodium (CD36i) stearoyl-CoA desaturase 1 (SCD1) siRNA (siSCD1) are selected inhibit uptake synthesis respectively. To this end, multiresponsive drug delivery nanosystem, HA@CD36i-TR@siSCD1 designed. The hyaluronic acid (HA) gel "shell" HA-TR nanosystem can release drugs response the acidic tumor microenvironment hyaluronidase, targeting (TR) cationic micellar "core" glutathione. This beneficial exogenous inhibition by CD36i endogenous siSCD1. established has good ability penetration ability, that synergistic effects, significantly restrain growth, invasion, metastasis PCa. Moreover, under high-fat conditions, tumors more sensitive treatment, almost no accumulation droplets observed HA@CD36i-TR@siSCD1-treated tumors, with enhanced antitumor immunity. Hence, study provides new treatment option patients, especially those diet.

Language: Английский

Adaptive immunity and metabolism DOI
Katherine Verbist, Piyush Sharma,

Helen M. Beere

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 157 - 190

Published: Jan. 1, 2025

Language: Английский

Citations

0
Combined Blockade of Lipid Uptake and Synthesis by CD36 Inhibitor and SCD1 siRNA Is Beneficial for the Treatment of Refractory Prostate Cancer DOI Creative Commons
Jiyuan Chen, Xiaoyan Yu, Gang Yang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Drug resistance is an important factor for prostate cancer (PCa) to progress into refractory PCa, and abnormal lipid metabolism usually occurs in which presents great challenges PCa therapy. Here, a cluster of differentiation 36 (CD36) inhibitor sulfosuccinimidyl oleate sodium (CD36i) stearoyl-CoA desaturase 1 (SCD1) siRNA (siSCD1) are selected inhibit uptake synthesis respectively. To this end, multiresponsive drug delivery nanosystem, HA@CD36i-TR@siSCD1 designed. The hyaluronic acid (HA) gel "shell" HA-TR nanosystem can release drugs response the acidic tumor microenvironment hyaluronidase, targeting (TR) cationic micellar "core" glutathione. This beneficial exogenous inhibition by CD36i endogenous siSCD1. established has good ability penetration ability, that synergistic effects, significantly restrain growth, invasion, metastasis PCa. Moreover, under high-fat conditions, tumors more sensitive treatment, almost no accumulation droplets observed HA@CD36i-TR@siSCD1-treated tumors, with enhanced antitumor immunity. Hence, study provides new treatment option patients, especially those diet.

Language: Английский

Citations

0